Glioblastoma Multiforme: Review of clinical candidates under development.
By Joseph Hedden, Senior Analyst
25 July 2014
I am an analyst at Datamonitor Healthcare, having previously completed a PhD in Structural and Molecular Biology at Univ...
Read full bio
The glioblastoma multiforme (GBM) clinical pipeline is dominated by targeted therapies and immunotherapies. Two immunotherapies, rindopepimut and DCVax-L, are in Phase III development. These drugs will avoid direct competition with the current standard of care Temodar by seeking approval as components of combination regimens that include Temodar. Datamonitor Healthcare has analysed the GBM pipeline across the US, Japan, and five major EU markets, validating pipeline candidates against a variety of sources. Novel and existing therapies have been benchmarked using clinical trial data.
How will our glioblastoma multiforme pipeline report benefit you?
- Avoid investment risks
Understand why late-stage compounds such as cilengitide and trabedersen were discontinued for use in brain cancer to identify how your own compound could avoid the same outcome.
- Gain competitive insight
Compare key pipeline drugs rindopepimut and DCVax-L against marketed therapies Temodar and Avastin in our clinical and commercial assessment model to better understand what clinical and commercial criteria future pipeline candidates must fulfil in order to compete.
- Identify investment opportunities
Explore the clinical and commercial limitations to both rindopepimut and DCVax-L in brain cancer to establish the unmet needs within the market, allowing you to identify where growth opportunities lie.
Key questions answered
- How will the approval of the Hospital Exemption compassionate access program by the Paul Ehrlich Institute affect uptake of DCVax-L?
- Why will rindopepimut’s commercial potential in the GBM market be limited?
- Why is the cost of DCVax-L anticipated to be high?
|Drug List:||Companies Mentioned:|
Posted in Oncology.